Last updated 2026-07-20
- Went public
- Acquired Colospan, Jun 2026
- Raised $31.9M Follow-on PO, May 2020
Total raised
$249.8M
Last: Public Offering Jul 2023
Stage
Public
Founded
2000
Headcount
10
HQ
Ramat Gan, Israel
Sector
Health Tech & Life Sciences
About
Galmed Pharmaceuticals Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing therapeutics for liver, metabolic, and inflammatory diseases. Their lead compound, Aramchol, is a first-in-class synthetic fatty acid-bile acid conjugate molecule. Initially developed for Non-Alcoholic Steato-Hepatitis (NASH) and liver fibrosis, Galmed has expanded its focus to include cardiometabolic diseases and gastrointestinal oncological indications. The company is also developing Amilo-5MER, a 5 amino acid synthetic peptide. Galmed became a public company in 2014 and is traded on NASDAQ under the ticker symbol GLMD.
Funding history · 11 rounds · $249.8M total
2024-10
Follow-on PO
$20.0M
2023-07
Follow-on PO
$7.0M
2022-07
Follow-on PO
$8.7M
2021-02
Follow-on PO
$9.5M
2020-05
Follow-on PO
$31.9M
2018-06
Follow-on PO
$75.0M
2018-04
Follow-on PO
$6.0M
2017-12
Follow-on PO
$35.0M
2017-08
Follow-on PO
$2.4M
2016-06
Follow-on PO
$16.0M
2014-03
IPO
$38.3M
Headcount over time
From 22 (2018-09) to 10 (2025-10) · -12 (-55%) · 33 points · source: Finder history + radar grounding
Q&A
- What is Galmed Pharmaceuticals' primary focus?
- Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for liver, metabolic, and inflammatory diseases.
- What is Galmed Pharmaceuticals' lead drug candidate?
- Galmed Pharmaceuticals' lead compound is Aramchol, a drug candidate for the treatment of NASH and fibrosis, currently in a Phase 3 registrational study.
- When did Galmed Pharmaceuticals go public?
- Galmed Pharmaceuticals went public on NASDAQ in March 2014.
- What was Galmed Pharmaceuticals' most recent public offering?
- In July 2023, Galmed Pharmaceuticals announced the pricing of a $7 million public offering.
- What is Galmed Pharmaceuticals' collaboration with the Hebrew University?
- Galmed Pharmaceuticals is collaborating with the Hebrew University on the development of Amilo-5MER, a 5 amino acid synthetic peptide, and recently initiated a first-in-human study for it.
- Has Galmed Pharmaceuticals been granted any recent patents?
- Yes, in February 2023, Galmed Pharmaceuticals announced the issuance of a new composition of matter patent for Aramchol meglumine salt.
- What is the employee count for Galmed Pharmaceuticals?
- Galmed Pharmaceuticals has 1-10 employees.
- Who is the current President & CEO of Galmed Pharmaceuticals?
- Allen Baharaff is the President & CEO of Galmed Pharmaceuticals.
Team · 8
Tuvia Gilat
Founder · Co-Founder
Allen Baharaff
Founder · Co-Founder & CEO
Senior CMC Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
metabolic-diseasedrug-discoverypharmaceuticalsmicrobiomebiopharmaceuticaloral-drugscrohn-s-diseasediabetespharma-companiesinflammatory-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Legal name | Galmed Pharmaceuticals Ltd. |
|---|---|
| Founded | 2000 |
| Employees (exact) | 10 |
| Market cap | $4.1M |
| Status reason | Public on NASDAQ on Mar, 2014 |
| Wikidata QID | Q19904023 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Colospan | 2026-06 |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Jul 2023 | ||||
| Feb 2021 | ||||
| Jun 2018 | ||||
| Jan 2018 | ||||
| Mar 2014 |
Radar intelligence
Web history (Wayback)
| Domain | galmedpharma.com |
|---|
Wikidata
| QID | Q19904023 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514953512 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2013-07-31 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 5 — violation (1), annual_report (4) |
| Registered address | דרך אבא הלל 16 רמת גן |
Recent registry events
| Date | Event |
|---|---|
| 2026-05-26 | עדכון הפרה |
| 2026-06-24 | דו~ח שנתי-עדכון תחום עיסוק |
| 2026-06-24 | דו~ח שנתי-עדכון כתובת |
| 2026-06-24 | דו~ח שנתי-עדכון מען דיגיטלי |
| 2026-06-24 | דו~ח שנתי-שינוי בהוראות בתקנון |